This work aimed at characterizing the role of peroxisome proliferator-activated receptors (PPAR)␣ in human white adipocyte metabolism and at comparing PPAR␣ and PPAR␥ actions in these cells. Primary cultures of human fat cells were treated with the PPAR␣ agonist GW7647 or the PPAR␥ agonist rosiglitazone. Changes in gene expression were determined using DNA microrrays and quantitative RT-PCR. Western blot and metabolic studies were performed to identify the biological effects elicited by PPAR agonist treatments. GW7647 induced an up-regulation of ␤-oxidation gene expression and increased palmitate oxidation. Unexpectedly, glycolysis was strongly reduced at transcriptional and functional levels by GW7647 leading to a decrease in pyruvate and lactate production. Glucose oxidation was decreased. Triglyceride esterification and de novo lipogenesis were inhibited by the PPAR␣ agonist. GW7647-induced alterations were abolished by a treatment with a PPAR␣ antagonist. Small interfering RNA-mediated extinction of PPAR␣ gene expression in hMADS adipocytes attenuated GW7647 induction of palmitate oxidation. Rosiglitazone had no major impact on glycolysis and ␤-oxidation. Altogether these results show that PPAR␣ can selectively up-regulate ␤-oxidation and decrease glucose utilization in human white adipocytes. (Endocrinology 151: 123-133, 2010) 
T he peroxisome proliferator-activated receptors (PPAR) are nuclear receptors involved in the control of energy homeostasis, inflammation, proliferation, and differentiation (1) . In particular, PPAR␣ and PPAR␥ play major roles in the regulation of lipid catabolism and anabolism, respectively (1) (2) (3) . Therefore, they constitute appealing therapeutic targets in the context of the growing obesity epidemic and its metabolic complications.
PPAR␥ is abundant in adipose tissue where it is essential for fat cell differentiation and maintenance of normal adipocyte function (4) . Activation of PPAR␥ by the thiazolidinedione (TZD) drug family leads to an improvement of insulin resistance in type 2 diabetic patients (1-3, 5, 6) . This effect is linked to enhanced triglyceride storage capacity in adipose tissue and modulation of the tissue secretory profile (3, 5) . Indeed, in adipocytes, activation of PPAR␥ by TZD stimulates the expression of genes involved in fatty acid uptake, transport, and storage such as lipoprotein lipase (LPL), fatty acid-binding protein 4 (FABP4), phosphoenolpyruvate carboxykinase 1 (PCK1), and acyl-coenzyme A (CoA) synthase (ACSS2). Moreover, PPAR␥ regulates the expression of adipokines such as adiponectin, leptin, and resistin (3) .
Conversely, PPAR␣ is a master regulator of fatty acid oxidation. Consistent with this function, it is mainly ex-pressed in tissues with high lipid catabolic capacities (1, 7) . PPAR␣ activation increases transcription of genes that encode proteins involved in fatty acid mitochondrial uptake and ␤-oxidation such as carnitine palmitoyltransferase 1 (CPT1) and very-long-chain acyl-CoA dehydrogenase (ACADVL). Its role extends beyond the control of fatty acid oxidation pathway through tissue-specific functions (8) . In the liver, PPAR␣ promotes gluconeogenesis and ketone body synthesis and is involved in lipoprotein assembly. In the heart, it participates in the regulation of the metabolic switch between glucose and lipid oxidation.
PPAR␣ is also well expressed in brown adipose tissue where, together with PGC1␣, it regulates key components of the thermogenic program (7, 9) . PPAR␣ agonists, Wy-14643 or fibrates, induce the transcription of the uncoupling protein-1 (UCP1) gene in brown adipocytes (10) . Because of its low expression, PPAR␣ has not been extensively investigated in white adipose tissue (WAT). However, some studies in rodents indicate that PPAR␣ has also a role in white fat cells. In mice, the activation of ␤ 3 -adrenergic receptors induces adipose tissue remodeling. In particular, expression of fatty acid catabolic enzymes and oxidative metabolism are increased, and those effects are partly mediated by PPAR␣ (11) . PPAR␣ is also mandatory for adipose tissue disappearance in hyperleptinemic rats, which is related to the induction of WAT oxidative enzymes (12) . In the WAT of PPAR␣ knockout mice, basal lipogenic flux and its response to a cholesterol-enriched diet are altered (13) . PPAR␣ agonists up-regulate the expression of adiponectin and of one of its receptors, ADIPOR2, in 3T3-L1 cells and in mice, whereas PPAR␣ invalidation abolishes the fibrate-induced rise in plasma adiponectin level (14, 15) . Finally oleoylethanolamide enhances lipolysis only in isolated mouse adipocytes that express PPAR␣ (16) .
In human adipose tissue, PPAR␣ is also expressed and its mRNA is negatively correlated with body mass index (1, 17) . However, there is a paucity of studies regarding PPAR␣ function, whereas extrapolation of rodent data to humans is hazardous because of noteworthy species differences. Indeed, the potency of PPAR␣ agonists differs between the mouse and human nuclear receptor (18) , and PPAR␣ activation in the liver leads to peroxisome proliferation and hepatocarcinoma in mice but not in humans (19) . Nonetheless, two studies stress the role of PPAR␣ in human adipocytes. Using Wy-14643, which is a potent and specific agonist for murine but not for human PPAR␣, an induction of fatty acid oxidation was observed (20, 21) . Moreover, we showed that glycerol kinase expression and activity are increased in human white adipocytes treated with the selective PPAR␣ agonist GW7647, which reflects the direct binding and activation of the glycerol kinase promoter by PPAR␣ (22) .
In the present work, we addressed the role of PPAR␣ in the regulation of human white adipocyte metabolism. Microarray analysis of transcriptional changes induced by pharmacological activation of PPAR␣ and PPAR␥ in differentiated fat cells revealed alterations of distinct sets of genes. PPAR␣ activation enhanced gene expression of the fatty acid oxidation pathway, whereas it down-regulated glycolysis genes. Accordingly, fatty acid oxidation and glycolysis were increased and decreased, respectively. Moreover, PPAR␣ activation diminished lipogenesis. PPAR␥ activation had no effect on ␤-oxidation and glycolysis. These results show that activation of PPAR␣ promotes fatty acid utilization in human white adipocytes.
Materials and Methods

Materials
GW7647, GW6471, etomoxir, and AICAR (2-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2yl]pyrrole-3-carboxamide) were purchased from Sigma-Aldrich (St. Louis, MO) and rosiglitazone (BRL49653) from Alexis Biochemicals (San Diego, CA). All chemicals were diluted in dimethylsulfoxide (DMSO) except AICAR, which was prepared in PBS.
Cell culture
Subcutaneous abdominal WAT was obtained from female subjects undergoing plastic surgery in agreement with French laws on biomedical research. Human preadipocytes from adipose tissue stromavascular fraction were differentiated as previously described (23, 24) . Only cultures with more than 70% of cells differentiated into lipid droplet-containing adipocytes at d 13 were selected for further experiments. Culture medium was replaced, and cells were treated with rosiglitazone(1 M) or GW7647 (1 M). When used, etomoxir (1 M) or GW6471 (10 M) was added at the same time as PPAR agonists. Vehicle was added to control cells. After 48 h treatment, medium was collected for metabolite measurements, and cells were either harvested for RNA or protein extraction or used in metabolic assays.
hMADS cells were cultured and differentiated as previously described (25) (26) (27) . For RNA interference assay, two small interfering RNA (siRNA) targeting PPAR␣ were used independently. The targeted sequences are for PPAR␣ 5Ј-GGATAGTTCTG-GAAGCTTT-3Ј or 5Ј-GGCCUCAGGCUAUCAUUAC-3Ј and for green fluorescent protein (GFP) 5Ј-GCAGCACGACUUCUUC-AAG-3Ј, and 200 pmol siRNA was electroporated in 2 million cells as previously described (27) . Six days after microporation, differentiated cells were treated with 1 M PPAR agonists, and after 48 h treatment, gene expression and oxidation assays were performed.
DNA microarray analysis
We treated four independent primary cultures from different subjects, with GW7647, rosiglitazone, or DMSO. After 48 h, total RNA was extracted with RNeasy mini kit (QIAGEN, Valencia, CA). Probe labeling, array hybridization and scan, data extraction, and preprocessing were performed as described (28) . Features with a signal to background ratio strictly less than 1.5 in both colors were discarded, and arrays were mean centered and normalized with Gene Cluster (29) . Differentially expressed genes between agonist and vehicle treatments were determined using significance analysis of microarray (SAM) one-class analysis with features having fewer than two missing values of four (30) . Data are accessible through GEO Series accession number GSE15862. SAM-ranked gene lists were used for gene ontology analysis using gene set enrichment analysis (31) . A Venn diagram built on GW7647-and rosiglitazone-regulated genes was used to list genes regulated only by GW7647, only by rosiglitazone, or by both agonists. The lists were analyzed with the PANTHER classification system to determine which biological processes were enriched (32) .
Quantitative RT-PCR analysis
One microgram of total RNA was treated with deoxyribonuclease I (amplification grade; Invitrogen). Reverse transcription and real-time quantitative PCR (qPCR) (Applied Biosystems, Foster City, CA) were performed as previously described (22) (supplemental Tables 1 and 2 , which is published as supplemental data on The Endocrine Society's Journals Online web site at http://mend.endojournals.org), and 18S rRNA was used as control. Results are expressed using the ⌬⌬Ct method.
Oxidation and esterification measurements
For palmitate oxidation assays, cells in six-well plates were incubated during 3 h in 2 ml Krebs Ringer buffer (125 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1.25 mM KH 2 PO 4 , 1.25 mM MgSO 4 ]chemp]7H 2 O, 25 mM NaHCO 3 ) containing 3% BSA, 500 M palmitic acid (Sigma), 1 Ci [ 14 C(U)]palmitic acid (PerkinElmer, Norwalk, CT). Medium was then transferred and acidified with 1 M sulfuric acid in closed vials containing a central well filled with benzethonium hydroxide. After 2 h incubation, wells were removed, and trapped 14 CO 2 was measured by liquid scintillation counting. Cells were washed and then scraped in cold buffer (0.25 M sucrose; 10 mM Tris HCl; 1 mM EDTA; 1 mM dithiothreitol, pH 7.4). Neutral lipids and aqueous soluble metabolites were separated by adding 5 vol chloroform/methanol (2:1) and 0.4 vol 1 M KCl/HCl. Lipids were separated by thinlayer chromatography to measure labeled palmitate incorporation into triglycerides. Specific activity was measured and used to calculate total oxidation as equivalent of oxidized palmitic acid.
For glucose oxidation assays, cells in six-well plates were incubated for 1 h in the same buffer containing 2% BSA, 10 mM HEPES, 2 mM glucose, and 1 Ci D-[ 14 C(U)]glucose (PerkinElmer). A 2-ϫ 2-cm Whatman 3M paper was taped on top of each well and wet with 100 l 1 N NaOH. After incubation, filter-trapped 14 CO 2 was measured by liquid scintillation counting. Medium-trapped 14 CO 2 was measured, and neutral lipids were extracted as described above. Glucose incorporation into fatty acid and glycerol was assessed as follows. Neutral lipids were dried and hydrolyzed in 1 ml 0.25 N NaOH in chloroform/methanol (1:1) for 1 h at 37 C. The solution was neutralized with 500 l 0.5 N HCl in methanol. Fatty acids and glycerol were separated by adding 1.7 ml chloroform, 860 l water, and 1 ml chloroform/methanol (2:1). Incorporation of 14 C into glycerol and fatty acids was measured by liquid scintillation counting of upper and lower phases, respectively. Specific activity was counted and used to determine the quantity of oxidized/incorporated glucose equivalent.
For oxidation assays, results were normalized to total protein content of cell extracts. Measurements were made in duplicate or triplicate.
Pyruvate and lactate concentration measurements
For medium lactate concentration determination, 5 l sample or standard was diluted in 200 l reaction buffer (0.4 M hydrazine; 0.2 M glycine; 0.5 mM nicotinamide adenine dinucleotide, pH 9.9), and variation of fluorescence emission (355/450) was measured before and 90 min after addition of rabbit muscle lactate dehydrogenase (Sigma) (33) . When lactate was measured in cell lysate, 50 l was used. Pyruvate concentrations were assessed with 25 l sample or standard in 200 l reaction buffer (34 mM K 2 HPO 4 ; 23 mM NaH 2 PO 4 ; 0.325 mM EDTA disodium; 50 M reduced nicotinamide adenine dinucleotide, pH 7). Absorbance at 340 nm was read before and 10 min after lactate dehydrogenase addition. Measures were made in duplicate or triplicate.
2-Deoxy-D-glucose (2DG) uptake assay
The day before the assay, insulin was removed from culture medium. Cells were incubated 45 min in 1 ml buffer (140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 2.5 mM MgSO 4 ⅐ 7H 2 O, 25 mM NaHCO 3 , 20 mM HEPES, 0.2% BSA) containing appropriate drugs with or without 100 nM insulin. Then 125 M 2DG and 0.4 Ci 2-[1,2-3 H(N)]deoxy-D-glucose (PerkinElmer) was added, and incubation was maintained for exactly 10 min. Culture plates were then put on ice and rinsed with 10 mM glucose in PBS and then with PBS. Cells were scraped in 0.05 M NaOH, and 2DG uptake was measured by liquid scintillation counting of cell lysate. The results were normalized to total protein content of cell lysates and expressed relative to DMSO without insulin sample.
Western blot
Cells were lysed in 50 mM Tris (pH 8), 0.5 mM dithiothreitol and 0.1% Nonidet P-40 supplemented with antiproteases and antiphosphatases. Lysates were centrifuged at 1000 ϫ g for 10 min at 4 C, and supernatants were resolved by 8% SDS-PAGE as previously described. Pyruvate dehydrogenase kinase 4 (PDK4) and hydroxyacyl-CoA dehydrogenase B (HADHB) antibodies were purchased from Abnova (Taipei City, Taiwan).
Statistical analyses
The number of independent cultures used for each assay is mentioned in the figure legends. Results are presented as mean Ϯ SEM unless otherwise indicated. All statistical analyses were performed with Wilcoxon nonparametric test on paired samples using SPSS version 17.0.
Results
PPAR␣ and PPAR␥ agonists regulate gene expression in human adipocytes
PPAR␣ is expressed in human white adipocytes albeit at a lower level than PPAR␥ (supplemental Fig. 1 ). We investigated the effects of PPAR␣ and PPAR␥ activation in human differentiated preadipocytes using DNA microarrays. SAM analysis showed that the PPAR␥ agonist rosiglitazone up-regulated 951 genes, whereas it down-regulated 695 genes (false discovery rate of 5%). The PPAR␣ agonist GW7647 up-regulated 1742 genes and down-regulated 1746 genes. A total of 1008 genes were regulated by both GW7647 and rosiglitazone. Therefore, although PPAR␣ and PPAR␥ share many targets in common, our results suggest that preferential targets also exist for each nuclear receptor.
To ascertain the relevance of our microarray approach, we performed RT-qPCR on 25 genes with significantly altered expression by GW7647 treatment. Overall, RT-qPCR data were in very good agreement with microarray data (Table 1). As an illustration of genes displaying different expression profiles, RT-qPCR confirmed that FAPB4 expression is more up-regulated by rosiglitazone than by GW7647. AACS mRNA was significantly down-regulated by both agonists. GK, a specific PPAR␣ target gene, was up-regulated to a larger extent by GW7647 than by rosiglitazone.
Fatty acid oxidation and glycolysis genes are differentially regulated by PPAR␣ and PPAR␥ agonists
To define whether PPAR activation altered specific cellular functions, we analyzed the ontology of GW7647-and rosiglitazone-regulated genes. Gene set enrichment analysis showed that the PPAR signaling pathway gene set was enriched for GW7647-and rosiglitazone-upregulated genes as expected. The PANTHER classification system pointed to genes of lipid metabolism-related pathways as a set of genes regulated by both agonists as well as sets of genes regulated only by GW7647 or by rosiglitazone. Among the genes regulated only by GW7647 were genes involved in glycolysis. Therefore, we focused the functional analysis of microarray data on fatty acid and glucose metabolism pathways.
As shown in Fig. 1A , PPAR␣ activation up-regulated four major genes involved in fatty acid oxidation. Indeed, CPT1B is the enzyme controlling fatty acyl-CoA entry into mitochondria for ␤-oxidation, HADHA and HADHB genes encode units forming the mitochondrial trifunctional protein, and ACAA2 gene encodes a protein catalyzing the last step of ␤-oxidation. Surprisingly, the PPAR␥ agonist also increased expression of these enzymes ( Table 1 and Fig. 1A ). However, the increase in CPT1B and HADHB induced by rosiglitazone was significantly lower than that induced by GW7647 (Table 1 and Microarrays were used to determine GW7647 and rosiglitazone effects in human white adipocytes. RT-qPCR were performed to confirm microarray data. Gene names are available in supplemental Tables 1 and 2 2A). This differential induction was confirmed at the protein level (Fig. 2B ). Gene ontology analysis indicated that GW7647 specifically decreased expression of seven glycolysis genes, six of which were confirmed by RT-qPCR (Table 1 and Fig. 1B) . After rosiglitazone treatment, only expression of aldolase C (ALDOC), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and muscle pyruvate kinase (PKM2) were decreased (Table 1) . ALDOC expression was repressed to a higher extent by GW7647 than rosiglitazone (Table 1 ). Microarray data indicated that the expression of Krebs cycle and oxidative phosphorylation genes were not altered by PPAR␣ or PPAR␥ agonist treatment.
GW7647, but not rosiglitazone, increases palmitate oxidation
Given that major enzymes of the ␤-oxidation appeared up-regulated, we measured palmitate oxidation in PPAR agonist-treated adipocytes. As shown in Fig. 2C , GW7647 increased palmitate oxidation by 80%, whereas rosiglitazone had no effect. Treatment of adipocytes with the CPT1 inhibitor etomoxir reduced palmitate oxidation by 70% in the presence or absence of PPAR agonist, indicating that palmitate oxidation measurement reflected mainly mitochondrial ␤-oxidation (Fig. 2D) .
GW7647, but not rosiglitazone, alters glucose fate
Gene expression profiling suggested that the PPAR␣ agonist was able to alter adipocyte glycolysis. Therefore, we measured glycolysis end product concentrations in culture medium. After 48 h PPAR agonist treatment, both pyruvate and lactate concentrations were reduced with GW7647 by 60%. Rosiglitazone slightly reduced pyruvate concentration and did not modify lactate concentration (Fig. 3, A and B) . Intracellular pyruvate concentrations were too low to be acutely quantified. However, intracellular lactate concentrations exhibited similar alterations as medium concentrations (data not shown).
Glycolysis depends directly on cellular glucose uptake. The GW7647-induced down-regulation of GLUT4 mRNA suggested that this pathway may be altered ( Table 1 , SLC2A4). After 48 h treatment, basal glucose uptake was not altered by PPAR␣ or PPAR␥ agonist, whereas it was strongly stimulated by insulin (data not shown). GW7647 reduced insulinstimulated glucose uptake, whereas rosiglitazone had no effect (Fig. 3C) . The GW7647-mediated decrease of insulin-stimulated glucose uptake was observed using 1, 10, and 100 nM insulin (data not shown).
Next, we measured glucose oxidation because it is the ultimate catabolic fate of the glycolytic product pyruvate after its conversion to acetyl-CoA by the pyruvate dehydrogenase complex (PDC). GW7647 and rosiglitazone significantly reduced glucose oxidation (Fig. 3D) . The PDK4 is a glucose metabolism key regulatory step because it inactivates the PDC and appeared up-regulated by PPAR␣ and PPAR␥ agonists in microarray data ( Table 1) . We confirmed that GW7647 and rosiglitazone increased PDK4 mRNA and protein levels (Fig. 3, E and F) .
GW7647 effects on ␤-oxidation and glycolysis are independent
Etomoxir treatment inhibited palmitate oxidation similarly in PPAR agonist-or vehicle-treated cells (Fig. 2D ). Lactate and pyruvate concentrations were unaffected by the lack of ␤-oxidation and were diminished 2-fold with GW7647 as in fatty acid-oxidizing cells (supplemental Fig. 2 and data not shown) . Thus, the GW7647-induced increase in ␤-oxidation is not required for reduced glycolytic flux in human adipocytes.
GW7647 inhibits lipogenesis in human adipocytes
PPAR␣ activation significantly altered fatty acid and glucose catabolism in adipocytes. We measured exoge- nous fatty acid esterification and de novo lipogenesis in an attempt to determine whether GW7647 also modified anabolic pathways. GW7647 significantly reduced palmitate incorporation into triglycerides, indicating that PPAR␣ agonist decreases fatty acid esterification (Fig.  4A ). Incubating adipocytes with oleic acid resulted in the same incorporation profile (data not shown). Glucose carbon incorporation into the glycerol and fatty acid moieties of lipids was measured. With GW7647, 40% less fatty acid was synthesized, showing that de novo lipogenesis is reduced (Fig. 4B) . GW7647 had no effect on glycerol synthesis (Fig. 4C ).
GW7647-induced metabolic alterations are mediated by PPAR␣
To verify that GW7647 alters fatty acid oxidation and glycolysis by a PPAR␣-dependent mechanism, we used GW6471, a PPAR␣ antagonist (34) . Basal levels of palmitate oxidation and medium lactate were unchanged by PPAR␣ blockade (Fig. 5, A and B) . When GW6471 and GW7647 were combined, the PPAR␣-induced decrease in lactate levels was abolished and the PPAR␣-induced increase of palmitate oxidation was partially inhibited (Fig.  5, A and B) . The PPAR␣ antagonist had no effect on rosiglitazone-treated cells.
To investigate the consequence of PPAR␣ knockdown on GW7647 effects, we used another human adipocyte model. hMADS cells are stem cells derived from infant adipose tissue that steadily differentiate into functional adipocytes (25, 26) . This cell line is amenable to reproducible and efficient siRNA-mediated knockdown, which proves difficult in differentiated primary adipocytes (27) . PPAR␣ silencing decreased PPAR␣ mRNA expression by 70% (Fig. 5C ). As in primary adipocytes, GW7647 up-regulated palmitate oxidation in hMADS cells (Fig.  5D ). PPAR␣ silencing strongly reduced basal and GW7647-enhanced palmitate oxidation (Fig. 5D ).
Discussion
We investigated the role of PPAR␣ in the control of human adipocyte metabolism and compared the effects of PPAR␣ and PPAR␥ activation. As previously reported, PPAR␣ and PPAR␥ share many target genes (35) . However, they also independently alter specific sets of genes. PPAR␣ activation with GW7647 regulated the expression of genes of the glucose and fatty acid metabolism pathways. GW7647 strongly increased palmitate ␤-oxidation by a PPAR␣-dependent mechanism. In parallel, GW7647 triggered a robust decrease in pyruvate and lactate concentrations and repressed glucose uptake and oxidation, de novo lipogenesis, and fatty acid esterification.
Because, in vivo, TZD induce an up-regulation in expression of lipid storage genes and an increase in sc adipose tissue mass, rosiglitazone-induced changes were expected (36) . At the transcriptional level, we observed an up-regulation of known targets such as FABP4 and PDK4 (2, 37) . A hypothesis for PPAR␥ antidiabetic action is the induction of a white to brown-like adipocyte shift associated with mitochondrial biogenesis and enhanced lipid oxidation capacity (38, 39) . Accordingly, Bogacka and colleagues (21) reported that PPAR␥ agonists increased fat oxidation in differentiated human adipocytes. We noticed a slight increase in CO 2 production after 48 h, but it was not statistically significant. Thus, in agreement with our previous study, we did not detect any robust induction in palmitate oxidation of rosiglitazone-treated human adipocytes (23) . Differences between our results and those of others in this regard could be explained by differences in treatment length, timing, and/or culture conditions. Rosiglitazone did not alter glucose uptake with or without insulin stimulation, which was in line with the unaltered GLUT4 mRNA level. This observation is apparently not in agreement with the known TZD ability to alleviate the PPAR␥-mediated repression of GLUT4 promoter in rat primary adipocytes (40) . However, it has also been shown that rosiglitazone does not change GLUT4 expression in differentiated 3T3-L1 adipocytes, whereas it increases GLUT4 expression when added during the differentiation (41) . In this study, rosiglitazone had moderate effects at the metabolic level, which is surprising in view of rosiglitazone's multiple effects in vivo. Nonetheless, TZD in vivo action is mediated by the differentiation of new adipocytes as well as the shrinkage of mature adipocytes, which reflect PPAR␥ role in adipocyte differentiation and normal function maintenance, respectively (42, 43) . In our model, adipocytes were already differentiated and were exposed to rosiglitazone only for 48 h, which was likely not sufficient to recapitulate in vivo PPAR␥ effects on adipocyte functions.
Human white adipocytes treated with a PPAR␣ agonist showed numerous significant alterations of gene expression. We showed that PPAR␣ activation strongly decreased lactate and pyruvate concentrations, which can result from three mechanisms: less glucose entry, glycolysis inhibition, and enhanced pyruvate utilization (supplemental Fig. 3 ). PPAR␣ agonist slightly decreased insulin-stimulated glucose uptake but not to an extent that can explain the lower pyruvate and lactate concentrations. Glucose oxidation was slightly diminished, which indicated that less pyruvate was catabolized through the Krebs cycle, suggesting a lesser pyruvate inflow or a Krebs cycle slowdown. Glucose incorporation into fatty acids was decreased by GW7647, whereas its incorporation into glycerol was unchanged. Therefore, the main pyruvate catabolic pathways were not increased and the fall in pyruvate and lactate concentrations is chiefly explained by a PPAR␣-induced inhibition of glycolysis, which was in line with the transcriptomic analysis. Indeed, we showed a coordinate PPAR␣-induced down-regulation of glycolytic gene expression, whereas microarray data indicated that PPAR␣ did not alter the gene expression of the Krebs cycle and respiratory chain enzymes. The involvement of PPAR␣ in glycolysis is also suggested by data from PPAR␣ Ϫ/Ϫ mouse isolated adipocytes, which produce higher lactate levels and oxidize more glucose compared with wild-type adipocytes (44) . Despite a strong inhibition of GLUT4 expression, we showed only a slight reduction in insulinstimulated glucose transport. Indeed, glucose uptake is mainly controlled by intracellular GLUT4 cycling and translocation to the plasma membrane (45) .
In addition to glycolysis inhibition, our results show that GW7647 doubled ␤-oxidation in agreement with the up-regulation of CPT1B and fatty acid oxidation enzymes. CPT1 is a classical PPAR␣ target gene. PPAR␣ induces its expression in liver, heart, and skeletal muscle (7, 46) . In human adipocytes, CPT1B is also a PPAR␣ target as shown in mouse adipose tissue (11, 12) . The PPAR␥-induced CPT1B up-regulation is puzzling because PPAR␥ is promoting lipid storage. However, this regulation has been reported in adipocytes from genetically obese mice treated with rosiglitazone (36) . Also in human differentiated adipocytes, three different PPAR␥ agonists were shown to increase CPT1B mRNA (21, 47) . Consistent with their respective species-related PPAR␣ activation potencies, GW7647 enabled a greater induction of lipid oxidation after 48 h treatment than Wy-14643 (21) . PPAR␣ activation altered lipid as well as glucose metab- Endocrinology, January 2010, 151(1):123-133 endo.endojournals.org olism in human adipocyte, which is reminiscent of a PPAR␣ role in other organs (8) . Indeed, PPAR␣ activates fatty acid oxidation in line with gene expression profiling when specifically overexpressed in mouse heart or skeletal muscle (46, 48) . The cardiac-specific overexpression is accompanied by a decrease in glucose oxidation, whereas skeletal muscle-specific PPAR␣ activation leads to wholebody glucose intolerance (46, 48) . Interestingly, Finck and colleagues (48) hypothesized that PPAR␣-induced fatty acid oxidation leads to ATP accumulation in skeletal muscle; therefore, inactivating AMP-activated kinase (AMPK) and thus inhibiting insulin-stimulated glucose uptake. However, because etomoxir did not prevent the PPAR␣induced decrease in lactate and pyruvate concentrations, it is unlikely that the rise in fatty acid oxidation caused glycolysis inhibition in adipocytes. Conversely, because adipocyte culture relies on glucose as energy substrate, the PPAR␣-induced decrease in glucose oxidation could activate AMPK. Thus, we tested whether AMPK activation with AICAR mimics GW7647 effects. AICAR strongly reduced glucose oxidation and glucose incorporation into glycerol and fatty acid, whereas it increased lactate concentration (supplemental Fig. 4 ). Thus, AICAR led to a rise in lactate, an opposite effect to PPAR␣. Altogether, AMPK does not appear as a key player in PPAR␣-induced metabolic alterations in adipocytes. Finally Randle's glucose fatty-acid cycle could be implied with ␤-oxidation limiting glucose oxidation by allosteric enzymatic feedback controls (49) . However, involvement of this cycle in our model is unlikely because we observed alterations in gene expression and because the etomoxir assay demonstrated that changes in glycolysis products were independent of ␤-oxidation. The metabolic alterations induced by PPAR␣ contrast with the lack of PPAR␥ effect. This is puzzling given that PPAR␣ and PPAR␥ target gene profiles are overlapping. There are, however, differences in induction of gene expression that may contribute to the selective effect of the A and B, Adipocytes were treated with 10 M GW6471, a PPAR␣ antagonist, and 1 M PPAR agonists or vehicle. After 48 h treatment, lactate medium concentration was quantified (A), and palmitate oxidation was measured (B) (n ϭ 6). *, P Ͻ 0.05. C and D, hMADS cells were differentiated into adipocytes and treated with agonists or vehicle for 48 h, whereas PPAR␣ was knocked down with an siRNA (siPPAR␣) (n ϭ 2). C, PPAR␣ expression assessed by RT-qPCR. D, After treatment, palmitate oxidation was measured. Fold changes were calculated relative to DMSO/siRNA for green fluorescent protein (siGFP), and means Ϯ SEM are plotted. Rosi, Rosiglitazone. PPAR␣ agonist. Regarding PPAR␣-induced up-regulation of fatty acid oxidation, CPT1B and HADHB showed a higher increase after GW7647 than rosiglitazone treatment. The data were confirmed at the protein level for HADHB. Moreover, CPT1 is allosterically inhibited by malonyl-CoA. Microarray data indicated that acetyl-CoA carboxylase-␣ (ACACA), which produces malonyl-CoA from acetyl-CoA, was significantly more repressed by PPAR␣ than by PPAR␥, whereas malonyl-CoA decarboxylase (MLYCD) was up-regulated by both agonists. Thus, the PPAR␣ agonist may decrease malonyl-CoA concentration and further exacerbate lipid mitochondrial entry. However, given the marked difference in palmitate oxidation between the two agonists, other mechanisms may intervene.
The shift in glycolysis seemed to be linked to PPAR␣induced coordinated down-regulation of many glycolysis genes, which was not seen with the PPAR␥ agonist. Because PDK4 has been shown as a gatekeeper responsible for the shift between glucose and fatty acid utilization, we investigated its regulation by PPAR agonists in human fat cells (50) . Both agonists induced a robust induction in PDK4 mRNA and protein levels. Therefore, regulation of PDK4 expression by GW7647 is unlikely to be responsible for glycolysis repression. It cannot, however, be ruled out that PDK4 enzyme activity is modified by posttranslational regulation. Finally, yet unidentified genes could be differentially regulated by PPAR␣ and PPAR␥. Recently, it was shown that CIDEA up-regulates lipid oxidation and decreases glucose oxidation in 3T3-L1 adipocytes, but in the present study, CIDEA was up-regulated by both agonists, ruling out its implication in this metabolic shift (51) .
Altogether, these results highlight the role of PPAR␣ in lipid and glucose homeostasis in human adipocytes. The relevance of this observation remains to be established in vivo. PPAR␣-induced lipid oxidation is of interest because it could promote fatty acid consumption in adipocytes and contribute to the control of body weight. In obese and insulin-resistant rats, fenofibrates reduce body weight gain and adiposity, which supports this hypothesis (52) . We have previously shown that PPAR␣ up-regulates glycerol phosphorylation, which when associated with an increase in lipolysis, could lead to fatty acid re-esterification into triglycerides and the creation of a futile cycle (22) . Recently, it was shown that lactate inhibits lipolysis in adipocytes; thus, the PPAR␣-induced reduction in lactate concentration could contribute to enhanced lipolysis (53) . Altogether, the combination of PPAR␣ agonist and lipolysis enhancer may be envisioned as a tool to promote fatty acid consumption and thus diminish triglyceride stores.
